Neuropsychological Comparison of Patients With Alzheimer’s Disease and Dementia With Lewy Bodies
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background and Purpose This study aimed to determine the neuropsychological differences between patients with early-stage Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) with a Clinical Dementia Rating (CDR) score of ≤1. Methods We examined 168 patients with AD (126 with CDR score=0.5, 42 with CDR score=1) and 169 patients with DLB (104 with CDR score=0.5, 65 with CDR score=1) whose diagnoses were supported by 18F-flobetaben positron-emission tomography (PET) and 18F-N-(3- fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane PET. Neuropsychological test scores were compared after controlling for age, sex, and education duration. Using a cutoff motor score on the Unified Parkinson’s Disease Rating Scale of 20, patients with AD were further divided into AD with parkinsonism (ADP+, n=86) and AD without parkinsonism (ADP−, n=82). Results At CDR scores of both 0.5 and 1, the DLB group had lower scores on the attention (digit-span forward at CDR score=0.5 and backward at CDR score=1), visuospatial, and executive (color reading Stroop test at CDR score=0.5 and phonemic fluency test, Stroop tests, and digit symbol coding at CDR score=1) tests than the AD group, but higher scores on the memory tests. The ADP− and ADP+ subgroups had comparable scores on most neuropsychological tests, but the ADP+ subgroup had lower scores on the color reading Stroop test. Conclusions Patients with DLB had worse attention, visuospatial, and executive functions but better memory function than patients with AD. Parkinsonism was not uncommon in the patients with AD and could be related to attention and executive dysfunction.
Abstract
Background and Purpose This study aimed to determine the neuropsychological differences between patients with early-stage Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) with a Clinical Dementia Rating (CDR) score of ≤1. Methods We examined 168 patients with AD (126 with CDR score=0.5, 42 with CDR score=1) and 169 patients with DLB (104 with CDR score=0.5, 65 with CDR score=1) whose diagnoses were supported by 18F-flobetaben positron-emission tomography (PET) and 18F-N-(3- fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane PET. Neuropsychological test scores were compared after controlling for age, sex, and education duration. Using a cutoff motor score on the Unified Parkinson’s Disease Rating Scale of 20, patients with AD were further divided into AD with parkinsonism (ADP+, n=86) and AD without parkinsonism (ADP−, n=82). Results At CDR scores of both 0.5 and 1, the DLB group had lower scores on the attention (digit-span forward at CDR score=0.5 and backward at CDR score=1), visuospatial, and executive (color reading Stroop test at CDR score=0.5 and phonemic fluency test, Stroop tests, and digit symbol coding at CDR score=1) tests than the AD group, but higher scores on the memory tests. The ADP− and ADP+ subgroups had comparable scores on most neuropsychological tests, but the ADP+ subgroup had lower scores on the color reading Stroop test. Conclusions Patients with DLB had worse attention, visuospatial, and executive functions but better memory function than patients with AD. Parkinsonism was not uncommon in the patients with AD and could be related to attention and executive dysfunction.
참고문헌 (45)
- McKhann GM, "The diagnosis of dementia due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.263~269 (2011)
- McKeith IG, "Diagnosis and management of dementia with Lewy bodies : fourth consensus report of the DLB consortium", Neurology, 89, pp.88~100 (2017)
- Duyckaerts C, "Classification and basic pathology of Alzheimer disease", Acta Neuropathol, 118, pp.5~36 (2009)
- McKeith IG, "Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies(DLB) : report of the consortium on DLB international workshop", Neurology, 47, pp.1113~1124 (1996)
- Irwin DJ, "The contribution of tau, amyloid-beta and alphasynuclein pathology to dementia in Lewy body disorders", J Alzheimers Dis Parkinsonism, 8, pp.444~ (2018)
- Walker L, "Clinical and neuropathological differences between Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies-current issues and future directions", J Neurochem, 150, pp.467~474 (2019)
- Hamilton RL, "Lewy bodies in Alzheimer’s disease : a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry", Brain Pathol, 10, pp.378~384 (2000)
- Auning E, "Early and presenting symptoms of dementia with Lewy bodies", Dement Geriatr Cogn Disord, 32, pp.202~208 (2011)
- Sasaki S, "High prevalence of parkinsonism in patients with MCI or mild Alzheimer’s disease", Alzheimers Dement, 14, pp.1615~1622 (2018)
- Ballard C, "Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer’s disease", Lancet, 351, pp.1032~1033 (1998)
- Petrou M, "Amyloid deposition in Parkinson’s disease and cognitive impairment : a systematic review", Mov Disord, 30, pp.928~935 (2015)
- Johnson DK, "Verbal and visuospatial deficits in dementia with Lewy bodies", Neurology, 65, pp.1232~1238 (2005)
- Kraybill ML, "Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both", Neurology, 64, pp.2069~2073 (2005)
- Toledo JB, "Clinical and multimodal biomarker correlates of ADNI neuropathological findings", Acta Neuropathol Commun, 1, pp.65~ (2013)
- Yoshizawa H, "Early neuropsychological discriminants for Lewy body disease : an autopsy series", J Neurol Neurosurg Psychiatry, 84, pp.1326~1330 (2013)
- Peng S, "Dynamic 18F-FPCIT PET : quantification of Parkinson’s disease metabolic networks and nigrostriatal dopaminergic dysfunction in a single imaging session", J Nucl Med, 62, pp.1775~1782 (2021)
- Albert MS, "The diagnosis of mild cognitive impairment due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.270~279 (2011)
- McKeith IG, "Research criteria for the diagnosis of prodromal dementia with Lewy bodies", Neurology, 94, pp.743~755 (2020)
- Kang SW, "Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies", Sci Rep, 11, pp.14394~ (2021)
- Kang Y, "Seoul Neuropsychological Screening Battery" (2012), Human Brain Research & Consulting Co.
- Christidi F, "Selective attention and the three-process memory model for the interpretation of verbal free recall in amyotrophic lateral sclerosis", J Int Neuropsychol Soc, 18, pp.809~818 (2012)
- 안현정, "Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring Cognitive Impairments in Dementia Patients", Journal of Korean Medical Science, 25(7), pp.1071~1076 (2010), 대한의학회
- Sadiq D, "Prodromal dementia with Lewy bodies and prodromal Alzheimer’s disease : a comparison of the cognitive and clinical profiles", J Alzheimers Dis, 58, pp.463~470 (2017)
- Yoon JH, "Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer’s disease in patients with mild cognitive impairment : a 5-year follow-up study", J Neurol Sci, 355, pp.174~179 (2015)
- Klatka LA, "Incorrect diagnosis of Alzheimer’s disease. A clinicopathologic study", Arch Neurol, 53, pp.35~42 (1996)
- Gaugler JE, "Characteristics of patients misdiagnosed with Alzheimer’s disease and their medication use : an analysis of the NACC-UDS database", BMC Geriatr, 13, pp.137~ (2013)
- Hohl U, "Diagnostic accuracy of dementia with Lewy bodies", Arch Neurol, 57, pp.347~351 (2000)
- McKeith I, "Revisiting DLB diagnosis : a consideration of prodromal DLB and of the diagnostic overlap with Alzheimer disease", J Geriatr Psychiatry Neurol, 29, pp.249~253 (2016)
- Kantarci K, "β-Amyloid PET and neuropathology in dementia with Lewy bodies", Neurology, 94, pp.e282~e291 (2020)
- Rogers SL, "The underlying mechanisms of semantic memory loss in Alzheimer’s disease and semantic dementia", Neuropsychologia, 46, pp.12~21 (2008)
- Randolph C, "Semantic fluency in Alzheimer’s, Parkinson’s, and Huntington’s disease : dissociation of storage and retrieval failures", Neuropsychology, 7, pp.82~88 (1993)
- Shin MS, "Clinical and empirical applications of the Rey-Osterrieth Complex Figure Test", Nat Protoc, 1, pp.892~899 (2006)
- Baddeley AD, "Working memory", Psychol Learn Motiv, 8, pp.47~89 (1974)
- Henry JD, "A meta-analytic review of verbal fluency performance following focal cortical lesions", Neuropsychology, 18, pp.284~295 (2004)
- Davis AS, "The relationship between the WAIS-III digit symbol coding and executive functioning", Appl Neuropsychol Adult, 19, pp.192~197 (2012)
- Shipstead Z, "The mechanisms of working memory capacity : primary memory, secondary memory, and attention control", J Mem Lang, 72, pp.116~141 (2014)
- Morris JC, "Clinical and pathological aspects of parkinsonism in Alzheimer’s disease. A role for extranigral factors?", Arch Neurol, 46, pp.651~657 (1989)
- Murray AM, "Damage to dopamine systems differs between Parkinson’s disease and Alzheimer’s disease with parkinsonism", Ann Neurol, 37, pp.300~312 (1995)
- Joyce JN, "Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson’s, Alzheimer’s with parkinsonism, and Alzheimer’s disease", Mov Disord, 12, pp.885~897 (1997)
- Mulet B, "Sustained and selective attention deficits as vulnerability markers to psychosis", Eur Psychiatry, 22, pp.171~176 (2007)
- Amato MP, "The Rao’s brief repeatable battery and stroop test : normative values with age, education and gender corrections in an Italian population", Mult Scler, 12, pp.787~793 (2006)
- Arbuthnott K, "Trail making test, part B as a measure of executive control : validation using a set-switching paradigm", J Clin Exp Neuropsychol, 22, pp.518~528 (2000)
- Fera F, "Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson’s disease", Brain Res Bull, 74, pp.75~83 (2007)
- Djamshidian A, "Stroop test performance in impulsive and non impulsive patients with Parkinson’s disease", Parkinsonism Relat Disord, 17, pp.212~214 (2011)
- Fornari LHT, "Striatal dopamine correlates to memory and attention in Parkinson’s disease", Am J Nucl Med Mol Imaging, 11, pp.10~19 (2021)